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Conclusions. We postulate that impaired VLDL1 clearancePatients with nephrotic-range proteinuria have apolipoprotein
in nephrotic-range proteinuria results from the appearance ofC and E deficient VLDL1.
particles deficient in apoCII, apoCIII, and apoE. VLDL1 apoCBackground. Impaired very low-density lipoprotein (VLDL)
deficiency is associated with the formation of smaller particlesclearance contributes to dyslipidemia in nephrotic-range pro-
with a high FC:PL ratio, and is likely to cause inefficient lipol-teinuria. VLDL can be subdivided into large light VLDL1 (Sf 60
to 400) and smaller, denser VLDL2 (Sf 20 to 60). In nephrotic- ysis. VLDL1 apoE deficiency is associated with smaller VLDL1
range proteinuria, the clearance of VLDL1 is delayed. VLDL1 particles but not altered VLDL1 surface lipid content, and may
lipolysis is influenced by apolipoprotein CII (apoCII) and reduce receptor-mediated clearance of this lipoprotein.
apoCIII, whereas apoE regulates receptor-mediated clearance.
Methods. To ascertain whether impaired VLDL1 clearance
was related to a deficiency in apolipoproteins on VLDL1, we
The dyslipidemia that characterizes nephrotic rangemeasured VLDL subfraction concentrations and VLDL1 apoli-
poprotein and lipid compositions in 27 patients with glomerular proteinuria results from a combination of increased pro-
disease and urinary albumin .2 g/24 h along with 27 age- and duction, impaired lipolysis, and reduced receptor-medi-
sex-matched controls. ated clearance of lipoproteins [1, 2]. This results in the
Results. Proteinuric patients had increased plasma VLDL1, classic finding of increased plasma cholesterol and low-VLDL2, apoCII, apoCIII (all P , 0.001), and apoE concentra-
density lipoprotein (LDL) cholesterol. Plasma triglycer-tion (P , 0.002). Patients appeared to have smaller VLDL1
particles, as assessed by triglyceride per particle (median 1 ides (TGs) are frequently raised [3], even in the context
interquartile range, moles per VLDL1 particle): patients, 4.9 of normal renal function [4, 5]. Very low-density lipopro-
(3.0 to 7.9) 3103; controls, 7.0 (4.6 to 15.7) 3103, P , 0.05, tein cholesterol (VLDL-C) is also increased [4, 6, 7], andwith reduced apoCII, 4.2 (3.1 to 8.2) versus 9.9 (7.4 to 23.2),
it is now recognized that excess VLDL-C is present inP , 0.0004; apoCIII, 16.6 (9.1 to 27.2) versus 29.3 (18.5 to
patients with nephrotic range proteinuria, normal creati-69.4), P , 0.02; and apoE content, 0.17 (0.08 to 0.44) versus 0.48
(0.31 to 1.31), P , 0.006. The VLDL1 surface free cholesterol nine clearance, and normal serum albumin levels [8].
to phospholipid results were increased in proteinuric patients Very low-density lipoprotein exists across a density
(0.55 6 0.17 vs. 0.40 6 0.18, P , 0.002, all mean 6 SD). For range of 0.93 to 1.006 g/mL and has a flotation rate thatall patients, VLDL1 apoCII, apoCIII, and apoE contents per
ranges from 20 to 400 Svedberg units (Sf). Within thisparticle were related to particle size (apoCII, r2 5 61.5%, P ,
spectrum, there is considerable heterogeneity, and the0.001; apoCIII, r2 5 75.8%, P , 0.001; apoE, r2 5 58.2%, P ,
0.001) and inversely to the free cholesterol to phospholipid lipoprotein class is commonly divided into large light
ratio (apoCII, r2 5 41.6%, P , 0.001; apoCIII, r2 5 38.8%, VLDL1 (Sf 60 to 400) and smaller denser VLDL2 (Sf 20 toP , 0.001; apoE, r2 5 11.7%, P , 0.05). Multivariate analysis
60). These two subfractions appear to be independentlysuggested that the relative lack of apoCII and apoCIII on
regulated. VLDL1 is TG rich, associated with raisedpatients VLDL1 was related to smaller particle size and in-
creased free cholesterol:phospholipid (FC:PL) ratio. Particle plasma TGs and overproduced in patients with insulin
size but not free cholesterol determined the apoE content of resistance [9]. Metabolic studies suggest that VLDL1 is
VLDL1. inefficiently converted to LDL [10]. In contrast, VLDL 2
has a greater cholesteryl ester content, is rapidly metabo-
lized to LDL, and is increased in patients with raisedKey words: dyslipidemia, lipolysis, clearance, hepatic production,
plasma triglyceride, atherogenic dyslipidemia, nephrotic syndrome. LDL-C [10].
Patients with nephrotic range proteinuria have an in-
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whereas the rise in VLDL2 results from both delayed fast. Samples were taken for the estimation of lipids and
lipoproteins, apolipoproteins, and VLDL subfractions,clearance and enhanced hepatic production [12, 13]. Ex-
cess plasma TG in the form of VLDL1 appears essential serum creatinine, and albumin. All patients collected a
24-hour urine sample over the preceding day for analysisfor the formation of small dense LDL [9, 14], a form of
LDL that is atherogenic [15] and associated with increased of urinary albumin excretion. The study was approved
by the ethics committee of Glasgow Royal Infirmary.cardiovascular risk [16, 17]. We have previously shown
that patients with nephrotic-range proteinuria possess All patients and controls gave written consent before
participating in the study.excess small dense LDL [11], and we postulate that the
delayed VLDL1 clearance and resultant hypertriglyceri- Plasma cholesterol, TG, VLDL cholesterol, LDL cho-
lesterol, and high density lipoprotein (HDL) cholesteroldemia are significant contributors to the atherogenic dys-
lipidemia prevalent in patients with nephrotic-range pro- were analyzed by a modification of the standard Lipid
Research’s Clinics protocol [21]. VLDL1 (Sf 60 to 400),teinuria.
The two pathways for clearing VLDL1 particles from VLDL2 (Sf 20 to 60), and IDL (Sf 10 to 20) were isolated
from plasma by a modification of the cumulative-gradi-the circulation are by hydrolysis using lipoprotein lipase
(LpL), which generates VLDL2 and then intermediate ent ultracentrifugation procedure described by Lind-
gren, Jensen, and Hatch [22]. LDL was isolated fromdensity lipoprotein (IDL), and by direct hepatic uptake
of VLDL1 via receptors, which recognize apolipoprotein fresh plasma by sequential ultracentrifugation. The TG,
free cholesterol, cholesteryl ester, phospholipid, and pro-E (apoE) [18]. Our laboratory has previously demon-
strated impaired VLDL clearance but normal chylomi- tein contents of the lipoproteins were assayed, and lipo-
protein concentrations were calculated as the sum of thesecron clearance in the nephrotic syndrome [19], with nor-
mal in vitro activity of LpL [11, 19]. Activation of LpL components [23]. ApoB, apoCII, apoCIII, and apoE were
analyzed from ethylenediaminetetraacetic acid (EDTA)depends on the cofactor apoCII on the VLDL particle,
whereas apoCIII inhibits this process [20]. The aim of plasma and the VLDL1 fraction using kits purchased
from Wako Pure Chemical Industries (Osaka, Japan).our study, therefore, was to measure the apoCII, apoC-
III, and apoE, in plasma and in VLDL1, along with
StatisticsVLDL1 lipid compositions to clarify the potential cause
of the impaired clearance leading to the excess VLDL1 in Statistical analyses were performed by using MINI-
TAB 11 for Windows (Minitab, Inc., State College, PA,the plasma of patients with nephrotic-range proteinuria.
USA). Any factors that were not normally distributed
were subjected to log transformation as previously de-
METHODS
scribed [14]. These included body mass index, plasma
Subjects TG, VLDL-C, HDL-C, total VLDL, VLDL1, VLDL2,
IDL, and LDL concentrations and the majority of apoli-Twenty-seven patients (22 males and 5 females) were
recruited from the outpatient clinic of the Glasgow Royal poprotein concentrations. Results are shown as either
means and standard deviation (SD) or median and inter-Infirmary Renal Unit according to the following inclusion
criteria: (1) urinary albumin excretion . 2.0 g/24 hours, quartile range (IQR). Samples were compared using the
two-sample t-test. Simple regression analysis was per-(2) serum creatinine , 300 mmol/L, and (3) primary glo-
merular disease. They were compared with 27 age- and formed to identify significant correlations. After fitting
regression lines, the slopes for patients and controls weresex-matched controls. Patients suffering from other dis-
eases or on treatment that might influence their lipid compared first to assess whether they were parallel and
then to see whether their intercepts differed. This wasprofile were excluded, specifically patients with underly-
ing liver disease, diabetes mellitus, amyloid, any neoplas- done using a general linear model (GLM). Multivariate
analysis of linear variables was performed using stepwisetic disorder, systemic lupus erythematosis, or taking thia-
zide diuretics, fat-soluble b blockers, corticosteroids, or regression. A GLM was used to perform multivariate
analysis if a categorical variable was involved.any other immunosuppressive agent. Treatment with
other antihypertensives or diuretics was permitted. Any
patient receiving lipid-lowering therapy had their lipid-
RESULTS
lowering medication stopped for a period of four weeks
Renal function, lipids, lipoproteins, andprior to inclusion in the study. All patients had a biopsy-
plasma apolipoproteinsproven diagnosis. The patients were compared with 27
age- and sex-matched controls who were either relatives Eight patients had a diagnosis of membranous nephrop-
athy, seven had IgA nephropathy with a further threeof patients attending the renal unit or members of labora-
tory staff. All controls were free of acute illness and had each having a diagnosis of mesangiocapillary glomerulo-
nephritis, minimal change, focal and segmental glomerulo-normal serum creatinine, albumin, and liver function
tests. Patients and controls attended after an overnight sclerosis, and chronic glomerulonephritis. Mean creatinine
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Table 2. Plasma concentration of VLDL1 apolipoproteins:Table 1. Plasma lipids, lipoproteins, VLDL subfractions, and
apolipoproteins (all median 1 IQR) Patients versus controls (all median 1 IQR)
Patients ControlsPatients Controls
(N 5 27) (N 5 27) P (N 5 21) (N 5 19) P
ApoB mg/dL 13.0 (6.1–26.2) 3.7 (0.9–6.3) ,0.003Age years 48 (29–62) 45 (30–60) NS
Body mass index 26.5 (25.1–30.2) 24.5 (22.8–28.6) NS ApoCII mg/dL 1.20 (0.49–1.87) 0.51 (0.33–0.77) ,0.002
ApoCIII mg/dL 4.14 (2.43–5.42) 1.57 (0.94–2.83) ,0.001Cholesterol mmol/L 6.8 (5.6–7.5) 5.1 (4.6–5.8) ,0.0001
Triglyceride mmol/L 2.2 (1.6–3.2) 1.0 (0.8–1.3) ,0.0001 ApoE mg/dL 0.14 (0.09–0.19) 0.13 (0.10–0.16) NS
VLDL-cholesterol mmol/L 1.0 (0.5–1.4) 0.3 (0.2–0.5) ,0.0001
LDL-cholesterol mmol/L 4.2 (3.7–5.4) 3.4 (2.8–4.0) ,0.003
HDL-cholesterol mmol/L 1.0 (0.8–1.2) 1.3 (1.1–1.7) ,0.003
VLDL total mg/dL 236 (172–364) 79 (52–113) ,0.0001
Table 3. Apolipoproteins and lipid content per VLDL1 particle:VLDL1 mg/dL 156 (57–212) 43 (24–74) ,0.0001
VLDL2 mg/dL 109 (75–140) 30 (21–43) ,0.0001 Patients versus controls (all moles per particle—median 1 IQR)
IDL mg/dL 80 (63–113) 44 (34–60) ,0.0001
Patients ControlsLDL mg/dL 351 (298–440) 292 (252–349) ,0.03
(N 5 21) (N 5 19) PApoB mg/dL 146 (112–179) 90 (68–98) ,0.0001
ApoCII mg/dL 6.2 (4.4–7.9) 3.1 (2.5–4.4) ,0.0001 ApoCII 4.2 (3.1–8.2) 9.9 (7.4–23.2) ,0.0004
ApoCIII mg/dL 30.0 (27.1–37.2) 17.7 (15.9–21.7) ,0.0001 ApoCIII 16.6 (9.1–27.2) 29.3 (18.5–69.4) ,0.02
ApoE mg/dL 4.3 (3.3–6.8) 3.5 (2.9–4.1) ,0.002 ApoE 0.17 (0.08–0.44) 0.48 (0.31–1.31) ,0.006
Triglyceride 4896 (3025–7912) 6979 (4590–15687) ,0.05Very low density lipoprotein (VLDL) total, VLDL1, VLDL2, IDL, and LDL 5
the total lipoprotein concentration (protein 1 triglyceride 1 free cholesterol 1 Total cholesterol 1758 (1393–2808) 1667 (1312–2885) NS
cholesteryl ester 1 phospholipid). Abbreviations are: LDL, low density lipopro- Free cholesterol 814 (515–1028) 759 (562–1474) NS
tein; HDL, high density lipoprotein; IDL, intermediate density lipoprotein; Apo, Phospholipid 1209 (977–2186) 1783 (1277–4091) NS
apolipoprotein; IQR, interquartile range.
was 139 6 56 mmol/L. Twenty patients had a creatinine
tients and 19 controls because the VLDL1 concentrationclearance (CCr; calculated using the Cockcroft & Gault was too low in some patients and controls to allow accu-formula) [24] greater than 50 mL/min, and in 15 patients,
rate measurement of apoCII, apoCIII, or apoE. If oneCCr was greater than 70 mL/min. Urinary albumin excre- of the VLDL1 apolipoproteins was unrecordable becausetion was 3.9 6 2.5 g/24 hours, and serum albumin was
of a low VLDL1 concentration, then all of the apolipo-well preserved at 35.0 6 6.7 g/L. Six patients had a serum
protein and composition results for that patient were
albumin , 32 g/L. Details of anthropometry and lipids ignored to avoid bias. In keeping with the increase in
are shown in Table 1. The patients were well matched total VLDL1 concentration, the concentration of apoBfor age and body mass index. Cholesterol, plasma TG, (P , 0.003), apoCII (P , 0.002), and apoCIII (P , 0.001)
and VLDL-C were all higher in patients with proteinuria were all elevated in the patients compared with controls.
compared with controls (all P , 0.0001). LDL-C was However, the concentration of VLDL1 apoE was notsimilarly raised, whereas HDL-C was reduced in the pa- increased. Each VLDL1 particle contains one apoB mol-
tients (both P , 0.003). There was a threefold to fourfold ecule; therefore, the quantity of apoCII, apoCIII, and
increase in the concentration of total VLDL, VLDL1, apoE on each VLDL1 particle was assessed by calculating
and VLDL2 in patients with proteinuria (all P , 0.0001). the molar ratio of each apolipoprotein to apoB in the
A twofold increase in IDL (P , 0.0001) was observed, VLDL1 subfraction (Table 3). This revealed VLDL1 par-
and the total LDL concentration was also increased. ticles in the patients with proteinuria to be deficient in
In keeping with the increase in total lipoproteins pres- apoCII, apoCIII, and apoE. In the case of apoE, this
ent, the total concentration of apoB was increased (Table deficiency was present to such an extent that it could be
1). Despite the threefold to fourfold increase in both calculated that between only one in three and one in
VLDL1 and VLDL2 in the patients with proteinuria, the five VLDL1 particles possessed an apoE moiety. The
plasma concentrations of apoCII and apoCIII were in- VLDL1 particles in the proteinuric group also had a
creased only twofold. A twofold increase in the plasma significantly lower TG content (P , 0.05) with a trend
concentration of IDL was also found in the patients toward lower surface phospholipid (P , 0.07). The total
with proteinuria. ApoE was only marginally increased and free cholesterol content of the particles did not differ
compared with controls. between the two groups.
The relative proportions of apolipoproteins to phos-
VLDL1 apolipoproteins and compositions: Patients pholipid on the surface of the VLDL1 particles further
versus controls demonstrated the relative deficiency of VLDL1 apolipo-
The concentrations of apolipoproteins present in the proteins. The ratio of apoCII to phospholipid (3.7 6 1.7
plasma VLDL1 fraction are seen in Table 2. The analysis vs. 5.8 6 2.1, P , 0.002), apoCIII to phospholipid (12.1 6
4.9 vs. 16.7 6 6.6, P , 0.03), and apoE to phospholipidof the VLDL1 apolipoproteins was performed on 21 pa-
Deighan et al: VLDL1, apoC and apoE deficiency in proteinuria 1241
(0.16 6 0.13 vs. 0.35 6 0.22, P , 0.02, all 31023) were
all significantly reduced compared with controls. In con-
trast, the ratio of free cholesterol to phospholipid
(FC:PL) was increased in the proteinuric patients (0.55 6
0.17 vs. 0.40 6 0.18, P , 0.002, all mean 6 SD).
Relationship between VLDL1 compositions and
VLDL1 concentration
Strong negative correlations were observed between
the plasma VLDL1 concentration and the number of
moles of apoCII and apoCIII per VLDL1 particle (Fig.
1). Thus, for all of the patients studied, as the VLDL1
concentration increased from 20 to 1000 mg/dL, the num-
ber of moles of apoCII per VLDL1 particle decreased
from about 53 to 1 and apoCIII per VLDL1 particle
decreased from about 150 to 3. A similar negative rela-
tionship was also observed between the moles of apoE
per VLDL1 and VLDL1 concentration, with apoE per
particle decreasing from about 5 to 0.02 (that is, 1 particle
in 50) as VLDL1 concentration increased (Fig. 1). A
strong negative relationship was also observed between
the moles of TG per VLDL1 particle (an index of particle
size) and the VLDL1 concentration (all subjects, r2 5
52.2%, P , 0.001; patients, r2 5 41.5%, P , 0.003; con-
trols, r2 5 71.1%, P , 0.001), indicating that as the
VLDL1 concentration increased, the size of the VLDL1
particles decreased. Weaker relationships were observed
between the VLDL1 concentration and the FC:PL ratio
(all subjects, r2 5 30.2%, P , 0.001; patients, r2 5 11.1%,
P 5 NS; controls, r2 5 25.7%, P , 0.03).
Regulation of VLDL1 apoCII and
apoCIII composition
To assess determinants of apoCII and apoCIII content
per VLDL1 particle, the relationship between apoCII
and apoCIII per VLDL1 particle and lipoprotein compo-
sition was analyzed. As the TG per particle increased
from 2 3 103 to 32 3 103 mol, so did apoCII and apoCIII
per particle (Fig. 2 and Table 4). Conversely, an inverse
relationship was seen between FC:PL (increasing from
0.17 to 0.98) and both apoCII and apoCIII per particle
(Fig. 3 and Table 4). An association was also observed
between TG per particle and FC:PL (all subjects, r2 5 Fig. 1. Very-low density lipoprotein1 (VLDL1) concentration (mg/dL)
22.7, P , 0.003). We proceeded to multivariate analysis versus apolipoprotein (apo)CII, apoCIII, and apoE per VLDL1 particle
(all mol/particle in a log:log plot). Symbols are: (d) patients; (1) con-to assess factors determining apoC per particle. We ana-
trols. In panel A, (solid line) r2 5 51.3% and P , 0.001 in patients;lyzed linear variables by stepwise regression and noted (dotted line) r2 5 55.0% and P , 0.001 in controls. In panel B, (solid
that for all subjects, TG per particle and FC:PL were line) r2 5 55.5% and P , 0.001 in patients; (dotted line) r2 5 34.3%
and P , 0.01 in controls. In panel C, (solid line) r2 5 22.6% and P ,independent predictors of apoCII per particle (total r2 5
0.03 in patients; (dotted line) r2 5 22.9% and P , 0.04 in controls.71.1%) and apoCIII per particle (total r2 5 80.5%). Mul-
tiple regression analysis using a GLM to include the
categorical variable “subject group” revealed that parti-
ject group” accounted for a mean difference of 1.5 molcle size, FC:PL, and “subject group” were all indepen-
of apoCII per VLDL1 and 1.3 mol of apoCIII per VLDL1,dent predictors of both apoCII and apoCIII per particle
with proteinurics having less of these apolipoproteins(Table 4). From the equation obtained from multiple
regression analysis, it could be estimated that the “sub- per particle for a given size and FC:PL ratio.
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jects revealed a weak relationship between apoE per
VLDL1 and FC:PL (r2 5 11.7 P , 0.05), no relationship
was seen if the analysis was performed for either patients
or controls (Fig. 3). On multivariate analysis, TG per
particle and subject group—but not FC:PL ratio—were
independent predictors of apoE per VLDL1 particle.
From the equation obtained from multiple regression
analysis, it could be estimated that the “subject group”
had a profound effect on apoE per particle, accounting
for a mean difference of 1.7 moles of apoE per VLDL1
(range of apoE per VLDL1, patients 0.04 to 2.0, controls
0.02 to 5.0 mol/particle).
Effect of renal function and hypoalbuminemia
In the patients with proteinuria, the relationship be-
tween the VLDL1 compositions and apolipoproteins did
not seem to be affected by renal function (as measured
by creatinine clearance; CCr) or serum albumin. Weak
relationships were seen between urinary albumin and
plasma apoB (r2 5 23.5%, P 5 0.01) and apoE (r2 5
23.5%, P 5 0.03), whereas serum albumin exhibited an
inverse relationship with plasma apoB (r2 5 25.3%, P ,
0.009). However, no other relationships were observed,
and there was no correlation between renal function and
VLDL1 apolipoprotein content. Fifteen patients had a
CCr greater than 70 mL/min, with 12 less than 70, whereas
among those patients whose VLDL1 apolipoproteins
could be measured, CCr was greater than 70 mL/min in
12 and less than 70 in 9. Comparing the two subgroups
revealed no differences in VLDL1 apolipoprotein con-
tent. Moreover, comparing the subgroup with CCr of
greater than 70 mL/min with the control group revealed
similar results to those obtained using all the proteinuric
patients. Plasma albumin was .32 g/L in 21 patients and
,32 in only 6 (.32 in 16 and ,32 in only 5 in those
patients whose VLDL1 apolipoproteins could be accu-
rately measured). Excluding the hypoalbuminemic pa-
tients did not significantly change the comparison of pa-
tients and controls.
DISCUSSION
Fig. 2. Triglycerides (TG) per VLDL1 particle versus apoCII, apoCIII, This study has confirmed that nephrotic range protein-and apoE per VLDL1 particle (all mol/particle in a log:log plot). In
uria is associated with an excess of both the larger lightpanel A, (solid line) r2 5 41.4% and P , 0.003 in patients; (dotted line)
r2 5 83.2% and P , 0.001 in controls. In panel B, (solid line) r2 5 VLDL1 and smaller dense VLDL2. It is recognized that
64.4% and P , 0.001 in patients; (dotted line) r2 5 65.9% and P , the excess VLDL1 is related to impaired clearance of0.001 in controls. In panel C, (solid line) r2 5 22.6% and P , 0.03 in
these TG-rich lipoproteins [12, 13]. Given that we havepatients; (dotted line) r2 5 22.9% and P , 0.04 in controls.
previously shown normal in vitro LpL activity in protein-
uria [11], we hypothesized that the impaired clearance
of VLDL1 may result from a relative lack of apolipopro-
Regulation of VLDL1 apoE composition teins on the VLDL1 particle. The data presented here
The relationship between apoE per particle and TG confirm that the VLDL1 particles in patients with pro-
per particle was similar to that found for apoC, indicating teinuria are relatively deficient in apoCII, apoCIII, and
that as the particle size increased, so did the apoE content apoE, with the compositional data in the control patients
corresponding closely to those obtained in earlier publi-(Fig. 2, Table 4). However, although analyzing all sub-
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Table 4. Univariate (U) and multivariate (M) analysis for regulation of apoCII, apoCIII and ApoE per VLDL1 particle: All patients
ApoCII ApoCIII ApoE
U r2 % M r2 % U r2 % M r2 % U r2 % M r2 %
TG per particle 61.5a 24.9a 75.8a 36.7a 58.2a 43.3a
FC:PL 41.6a 5.2b 38.8a 2.8c 11.7c NS
Subject group — 5.3b — 2.5c — 4.2d
Abbreviations are: r2, coefficient of determination; TG, triglycerides; FC:PL, ratio of free cholesterol to phospholipid.
aP , 0.001, bP , 0.01, cP , 0.05, dP 5 0.05.
cations [25]. This study has also suggested that the apoC served. We proceeded to explore the relationships be-
tween VLDL1 concentration, lipoprotein size, and thedeficiency is related to a combination of the presence of
smaller VLDL1 particles, and VLDL1 particles, which are lipid and apolipoprotein content of VLDL1.
It is traditionally accepted that LpL activity is regu-relatively enriched in free cholesterol, with an increased
ratio of free cholesterol to phospholipid (FC:PL) on their lated by the balance between apoCII (a cofactor activat-
ing LpL-induced lipolysis of TG-rich lipoproteins) andsurface. The VLDL1 apoE deficiency in proteinuria was
related to the presence of smaller VLDL1 particles but apoCIII (a cofactor that inhibits LpL). It is therefore
noteworthy that there was no observed difference in thewas not explained by altered lipid composition.
Patients with nephrotic-range proteinuria are hetero- ratio of CII:CIII when comparing patients with controls.
The apoCII:CIII ratio also remained constant as VLDL1geneous in terms of clinical diagnosis, renal function,
and plasma albumin. Indeed, some studies investigating particle size decreased or FC:PL increased. This is in
contrast to the reported situation in other hypertriglycer-dyslipidemia in the nephrotic syndrome only require pa-
tients to have nephrotic range proteinuria without neces- idemic conditions, where apoCIII increases and apoCII
decreases with a reduction in the apoCII:CIII ratio assarily being hypoalbuminemic [26, 27]. Metabolic studies
have shown impaired VLDL1 clearance and increased plasma TG and VLDL1 concentration increase [28, 29].
There is evidence to suggest that the inhibitory effect ofVLDL2 production in patients with nephrotic-range pro-
teinuria who were predominantly normoalbuminemic apoCIII on LpL is not competitive [30]. Moreover, the
ratio of apoCII:CIII is not correlated with plasma LpL-[12]. More recently, patients with the nephrotic syndrome
and normal renal function have been shown to have a inhibitory activity [30]. This suggests that it is the abso-
lute amount of VLDL1 apoCIII rather than the ratio oftwofold increase in VLDL1 concentration, with a four-
fold increase in VLDL2 and reduced VLDL1 and VLDL2 apoCII:CIII that determines LpL activity. Therefore, one
would expect the low concentration of VLDL1 apoCIIIclearance [13]. In our study, neither the heterogeneity
in renal function or plasma albumin seem to have influ- to result in decreased inhibition of LpL allowing apoCII-
mediated activation of the enzyme. However, we postu-enced VLDL1 apolipoprotein composition. As a result,
the proteinuric patients were treated as a whole group. late that the concentration of VLDL1 apoCII observed
is so low that impaired activation of the enzyme results,A clear relationship is seen between the number of
moles of apoCII, apoCIII, and apoE per VLDL1 particle contributing to the delayed clearance of TG-rich lipopro-
teins observed in this population. The reduction in apoEand the VLDL1 concentration. Thus, in both patients
and controls, as the VLDL1 concentration increases, the per particle in the proteinuric patients is likely to have
further consequences for clearance of VLDL as the VLDLapolipoprotein content of VLDL1 particles decreases.
However, a clear relationship was also seen between the receptor, LDL-receptor related protein and LDL recep-
tor are thought to use apoE as their ligand [18]. Indeed,particle size (that is, TG per particle) and the apolipo-
protein content of each particle. Moreover, the patients it can be calculated that between 67 and 80% of the
VLDL1 particles in the patients are devoid of apoE.with proteinuria tended to have smaller VLDL1 particles
compared with controls. Therefore, it was important to The data presented suggest that in the entire popula-
tion studied, the apoC content of the VLDL1 particlesdecide whether the observed VLDL1 apolipoprotein de-
ficiency was simply a consequence of having smaller par- is determined by (1) particle size, (2) the surface ratio
of FC:PL, and (3) the presence of proteinuria. Across aticles or whether it was also independently related to
the presence of proteinuria. From our data, we con- wide range of VLDL1 concentrations, the increase in
VLDL1 size (increased TG per particle) should lead tocluded that for apoCII, apoCIII, and apoE, particle size
and lipid composition (that is, the FC:PL ratio) did not an increase in the surface area of the lipoproteins and
a greater ability to accumulate apoCII and apoCIII.appear to explain all of the differences in apolipoprotein
content between the patients and controls, and an addi- Therefore, the finding of smaller VLDL1 particles in the
patients with proteinuria is likely to have a profoundtional effect of being in the proteinuric group was ob-
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independently associated with the surface FC:PL ratio.
Free cholesterol forms a hydrogen bond with phospho-
lipid, and a phospholipid layer is saturated when FC:PL
approaches 1.0 [31]. We hypothesize that the reduction
in apoC observed as FC:PL increases is caused by the
changing nature of the phospholipid layer as it becomes
enriched in free cholesterol [32]. It is interesting to ob-
serve that in Figure 3, as this ratio approaches unity, the
number of apoCs per VLDL1 decreases dramatically,
suggesting that the lack of low molecular weight apolipo-
proteins in the patients VLDL1 is also due to the satura-
tion of the phospholipid layer with free cholesterol. Small
apolipoproteins such as apoC are known to bind to VLDL
by penetrating the surface phospholipid matrix of lipo-
proteins and embed their amphipathic helical structures
in the phospholipid layer [20]. If the phospholipid layer
is not fluid enough, because of the excess FC, then it is
likely that apoCs will not be able to bind. Therefore,
we postulate that even in the VLDL1 range, the free
cholesterol enrichment of the surface leads to an inability
to incorporate apoC by exchange from HDL, resulting
in apoC-deficient particles. The observation that there
was no independent association between apoE per parti-
cle and FC:PL suggests that inter-lipoprotein transfer in
plasma is less important for apoE. There is evidence
to suggest that free cholesterol is overproduced in the
nephrotic syndrome [33]; however, indirect assessment
of cholesterol synthesis does not support this evidence
[34]. Whether the increased FC:PL ratio results from
overproduction of free cholesterol or is a consequence
of the smaller particle size will require further study.
However, it is interesting to note that apoE may have
a role in VLDL production, with apoE-deficient cells
producing smaller VLDL than controls [35]. Whether a
plasma deficiency in apoE plays a role in the appearance
of smaller VLDL1 in the patients with proteinuria re-
mains to be determined.
After accounting for the effect of particle size and
surface FC:PL on VLDL1 apolipoprotein content, there
remained an effect of being in the proteinuric group.
Although plasma apoCII, apoCIII, and apoE were in-
creased in the patients with proteinuria, this increase
may be related to an increase in apoB-containing lipo-
Fig. 3. Free cholesterol to phospholipid (FC:PL) ratio versus apoCII, proteins. Whether a relative plasma deficiency in apoC
apoCIII, and apoE per VLDL1 particle (all mol/particle). In panel A, and apoE is present in proteinuric patients will require(solid line) r2 5 19.2% and P , 0.05 in patients; (dotted line) r2 5
further study. A further limitation of the study is that as30.0% and P , 0.02 in controls. In panel B, (solid line) r2 5 28.3%
and P , 0.02 in patients; (dotted line) r2 5 29.7% and P , 0.02 in a descriptive analysis of lipoprotein composition, it is not
controls. In panel C, (solid line) r2 5 1.5% and P 5 NS (not significant) possible to determine whether the abnormalities presentin patients; (dotted line) r2 5 6.2% and P 5 NS in controls.
are a cause or a consequence of the abnormal lipoprotein
metabolism. Metabolic studies involving analysis of rates
of production and clearance of apolipoproteins will be
effect on the apolipoprotein content of these particles. required to clarify this point.
Apart from apolipoproteins, the main surface constit- In summary, we have demonstrated that patients with
uents of lipoproteins are free cholesterol and phospho- nephrotic-range proteinuria possess VLDL1 particles de-
ficient in apoCII, apoCIII, and apoE. We have suggestedlipid. The apoCII and apoCIII content per particle was
Deighan et al: VLDL1, apoC and apoE deficiency in proteinuria 1245
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